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Abbreviations 33 
CFSE  5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester 34 
IPSE  Interleukin-4 inducing principle from Schistosoma mansoni eggs 35 
MESNA 2-mercaptoethanesulfonic acid 36 
NLS  Nuclear localization sequence 37 
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Abstract  38 
Chemotherapy-induced hemorrhagic cystitis is characterized by bladder pain and 39 
voiding dysfunction caused by hemorrhage and inflammation. Novel therapeutic options 40 
to treat hemorrhagic cystitis are needed. We previously reported that systemic 41 
administration of the Schistosomiasis haematobium-derived protein H-IPSEH06 (IL-4-42 
inducing principle from Schistosoma mansoni eggs), is superior to 3 doses of MESNA in 43 
alleviating hemorrhagic cystitis. Based on prior reports by others on S. mansoni IPSE 44 
(M-IPSE) and additional work by our group, we reasoned that H-IPSE mediates its 45 
effects on hemorrhagic cystitis by binding IgE on basophils and inducing IL-4 46 
expression, promoting urothelial proliferation, and translocating to the nucleus to 47 
modulate expression of genes implicated in relieving bladder dysfunction. We 48 
speculated that local bladder injection of the S. haematobium IPSE ortholog IPSEH03, 49 
hereafter called H-IPSEH03, might be more efficacious in preventing hemorrhagic cystitis 50 
compared to systemic administration of IPSEH06. We report that H-IPSEH03, like M-IPSE 51 
and H-IPSEH06, activates IgE-bearing basophils in an NFAT reporter assay, indicating 52 
activation of the cytokine pathway. Further, H-IPSEH03 attenuates ifosfamide-induced 53 
increases in bladder wet weight in an IL-4-dependent fashion. H-IPSEH03 relieves 54 
hemorrhagic cystitis-associated allodynia and modulates voiding patterns in mice. 55 
Finally, H-IPSEH03 drives increased urothelial cell proliferation suggesting that IPSE 56 
induces bladder repair mechanisms. Taken together, H-IPSEH03 may be a potential 57 
novel therapeutic to treat hemorrhagic cystitis by basophil activation, attenuation of 58 
allodynia and promotion of urothelial cell proliferation. 59 
Key words: IL-4, IPSE, hemorrhagic cystitis, schistosomiasis  60 
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Introduction 61 
Ifosfamide and other alkylating chemotherapy agents are used in a wide variety 62 
of malignancies including leukemias, soft tissue sarcomas, and testis cancer. The liver 63 
metabolizes ifosfamide into acrolein, which is excreted in the urine and has a 64 
deleterious effect on the urothelium. Hemorrhagic cystitis is characterized by bladder 65 
edema, hemorrhage, urothelial denudation, and infiltration of inflammatory cells. This 66 
condition affects up to 40% of ifosfamide-exposed patients, resulting in hematuria, 67 
dysuria, bladder spasms, and urinary frequency (10). Hemorrhagic cystitis is a 68 
challenging condition to manage, and often requires hospitalization and invasive 69 
treatments (18).  70 
Accordingly, strategies to attenuate ifosfamide-induced hemorrhagic cystitis, 71 
such as administration of 2-mercaptoethanesulfonic acid (MESNA), bladder irrigation, or 72 
hyperhydration often achieve suboptimal protection for patients (18). Despite use of 73 
existing therapies, a majority of patients have symptomatic and/or histologic evidence of 74 
hemorrhagic cystitis (16).  As an alternative to current management approaches, 75 
Macedo et al. reported that administration of recombinant interleukin-4 (IL-4) attenuated 76 
the effects of ifosfamide in a mouse model of hemorrhagic cystitis (17). The importance 77 
of IL-4 in this model was demonstrated by administration of anti-IL4 antibody to 78 
ifosfamide-exposed, wild type mice and administration of ifosfamide to IL-4-deficient 79 
mice, both of which resulted in worsened hemorrhagic cystitis (23). Interestingly, 80 
ifosfamide administration increased endogenous production of IL-4, suggesting the 81 
existence of intrinsic regulatory mechanisms to control inflammation in response to 82 
ifosfamide (17). However, systemic administration of IL-4 to treat hemorrhagic cystitis 83 
Downloaded from www.physiology.org/journal/ajprenal at Univ of Nottingham (128.243.002.047) on May 8, 2019.
2 
 
may not be a realistic option due to pleiotropic effects and a short in vivo half-life of this 84 
cytokine (20). Therefore, alternative strategies to increase expression of IL-4 would be 85 
needed in order to leverage this cytokine for therapeutic treatment of hemorrhagic 86 
cystitis.  87 
One alternative may be the interleukin-4 inducing principle from Schistosoma 88 
mansoni eggs (IPSE), the most abundant protein secreted by S. mansoni eggs. IPSE 89 
attenuates inflammation via multiple mechanisms, including binding immunoglobulins to 90 
stimulate IL-4 release, sequestering chemokines, and translocating to the nucleus to 91 
modulate transcription (13, 19, 22, 27). We have previously reported that similar to the 92 
S. mansoni ortholog of IPSE, M-IPSE, several S. haematobium orthologs, referred 93 
hereafter as H-IPSE, bind to IgE on mast cells and basophils and upregulate the 94 
expression of IL-4 (22). Through sequencing of S. haematobium cDNA transcripts, we 95 
identified two main clades of H-IPSE – H-IPSEH03 and H-IPSEH06 --with conservation of 96 
functional domains present in M-IPSE, such as 7 cysteines important for intra- and 97 
intermolecular bonds, a nuclear translocation sequence (NLS), and 2 N-linked 98 
glycosylation motifs. IPSE has a homodimeric structure with a molecular weight of 38-99 
40 kDa. Importantly, both H-IPSEH03 and H-IPSEH06 translocate into urothelial cell nuclei 100 
(22).  101 
Initial animal experiments with H-IPSE focused on the effect of systemic 102 
administration of H-IPSEH06 by tail vein injection (19). Tail vein injection of H-IPSEH06 103 
attenuates ifosfamide-induced bladder hemorrhage in an IL-4 and NLS-dependent 104 
manner. Furthermore, mice treated with H-IPSEH06 prior to ifosfamide exposure 105 
demonstrated fewer spontaneous pain behaviors and had a higher threshold for evoked 106 
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pain responses (19). We speculated that direct injection of IPSE into the bladder wall 107 
would have multiple advantages over intravenous injection, including avoidance of side 108 
effects caused by systemic administration (although none have been identified to date), 109 
and potentially decreased dosage to achieve a therapeutic effect. Further, experiments 110 
in our lab have shown that H-IPSEH03 induces a more robust proliferative response in 111 
vitro when compared to H-IPSEH06 (unpublished data) making H-IPSEH03 a more 112 
attractive target to investigate the role of H-IPSEH03  in promoting urothelial repair. The 113 
aim of this work was to determine whether direct bladder wall injection of H-IPSEH03 114 
attenuates bladder inflammation, voiding dysfunction and pain in a mouse model of 115 
hemorrhagic cystitis.  116 
 117 
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Materials and Methods 118 
Mice 119 
Six to 8-week-old female C57BL/6 mice (Charles River Laboratories, Wilmington, 120 
MA) were housed in cages with free access to water and standard chow and 12 hour 121 
light-dark cycles. Mice were acclimated for at least 7 days prior to experimentation. The 122 
animal protocol (#18-03) was approved by the Institutional Animal Care and Use 123 
Committee at the Biomedical Research Institute (Rockville, MD). Our institutional animal 124 
care and use committee guidelines follow the U.S. Public Health Service Policy on 125 
Human Care and Use of Laboratory Animals.  126 
 127 
Bladder wall injections 128 
Mice received a single bladder wall injection of H-IPSEH03 24 hours prior to 129 
exposure to ifosfamide. Mice were anesthetized with 2% continuous isoflurane on a 130 
heating pad. Procedures were performed using sterile technique. For pain control, 0.1 131 
mg/kg buprenorphine and 0.1 mg/kg bupivacaine were injected subcutaneously. A 132 
midline laparotomy was performed sharply and the bladder delivered through the 133 
incision. Mice were divided into 3 groups receiving sham, control or IPSE. A 30-gauge 134 
needle was used to inject a 1:1 v/v mixture of Low Growth Factor Matrigel (Corning, 135 
Corning, New York) and PBS containing 25 µg mouse albumin (control) or 25 µg H-136 
IPSE (IPSE) (Figure 1). Sham mice received a midline laparotomy only. Incisions were 137 
closed in 2 layers using 5-0 Vicryl on the abdominal wall and 5-0 silk to close skin. 138 
Bacitracin was applied to the incision. The mice were recovered on a heating pad. 139 
Twenty-four hours later mice were injected with 400 mg/kg ifosfamide (Sigma-Aldrich, 140 
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St. Louis, MO). Mice who received anti-IL4 antibody (inVivoMab 11B11, BioXcell, West 141 
Lebanon, NH) received 10 ng by intraperitoneal (IP) injection 30 minutes before 142 
ifosfamide. Control mice received IP injections of phosphate-buffered saline (PBS).  At 143 
12 hours, mice were euthanized, their bladders removed and weighed. Bladders were 144 
then subjected to additional analysis detailed below. Each experiment was performed 145 
on 3-4 mice per group. Figures are pooled from 3 experiments. 146 
Tail vein injections 147 
Mice were anesthetized with 2% continuous isoflurane on a heating pad. A 30-148 
gauge needle was used to inject PBS containing 25 µg mouse albumin or 25 µg H-149 
IPSEH03 (IPSE) in PBS. The mice were recovered on a heating pad. Twenty-four hours 150 
later mice were injected with 400 mg/kg ifosfamide (Sigma-aldrich, St. Louis, MO). Mice 151 
who received anti-IL4 antibody (inVivoMab 11B11, BioXcell, West Lebanon, NH) 152 
received 10 ng by intraperitoneal (IP) injection 30 minutes before ifosfamide. Control 153 
mice received IP injections of phosphate-buffered saline (PBS).  At 12 hours, mice were 154 
euthanized, bladders were removed and weighed.  155 
Recombinant IPSE protein 156 
Recombinant IPSE protein was generated as previously described (1,2). One 157 
milligram of plasmid DNA was purified using a GeneElute HP endotoxin-free plasmid 158 
Maxiprep kit (Sigma-Aldrich), and incubated with 3 mg linear 25 kDa polyethylenimine 159 
(PolySciences, Warrington, PA) at 1 mg/mL. Finally, the plasmid was diluted in 10 mL 160 
sterile PBS for each transfection in 1L. Human embryonic kidney 293-6E cells (7) 161 
expressed secreted recombinant protein for 5 days in suspension culture using 162 
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FreeStyle 293 Medium (Thermo Fisher Scientific, Waltham, MA, USA) (Figure 2A). 163 
Protein was purified over 10 mL Ni-NTA resin (Qiagen, Germantown, MD, USA), 164 
washed with 25 mM imidazole PBS, pH 7.4, and eluted with 300 mM imidazole PBS, pH 165 
7.4 containing 50 mM arginine. Eluted protein was concentrated with an Amicon Ultra 166 
Centrifugal Filter Unit (EMD Millipore, Billerica, MA, USA) followed by purification with a 167 
Hiload 16/600 Superdex 200 Column (GE Healthcare, Waukesha, WI, USA). Nuclear 168 
localization mutants were generated using site-directed mutagenesis. These mutants 169 
(124-PKRRRTY-130 to 124-PKAAATY-130) disrupted the C-terminal NLS (NLS; H-170 
IPSEH03NLS) (2). To decrease the risk of pyrogen contamination, FPLC machines and 171 
Hiload columns were cleaned with 0.5 M NaOH for a minimum of 2 hours continuous 172 
flow and then washed with PBS, pH 7.4.  173 
SDS-PAGE and Western blotting 174 
 Purified protein was separated on 4-20% gradient gels by SDS-PAGE in 15 µL 175 
aliquots (Mini-Protean TGX Precast Gels, Biorad). Separated proteins were then 176 
transferred to a 0.2 µM nitrocellulose membrane. Membranes were incubated in 177 
blocking buffer for 1 hour (5% [wt/vol] dried skim milk, 0.01% [vol/vol] Tween 20, and 178 
Tris-buffered saline [TBS]) on a shaker at room temperature. Primary antibody was 179 
mouse anti-His (GE-Healthcare) diluted at 1:500 and incubated overnight at 4˚C 180 
followed by washing in TBS containing 1% Tween 20 for 5 min x 3. Membranes were 181 
then incubated with secondary antibody--HRP-conjugated anti-mouse IgG (Sigma-182 
Aldrich) -- for 1 hour at room temperature followed by 3 additional washes. Imaging was 183 
performed using Pierce ECL Western Blotting Reagent (ThermoScientific Fisher) on a 184 
Fuji LAS4000 imager. 185 
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Basophil activation with recombinant M-IPSE, H-IPSEH03 and H-IPSEH06 186 
Basophil activation was quantified as previously described (28), using a 187 
luciferase based humanized IgE reporter system. The cell line reports IgE-dependent 188 
NFAT translocation to the nucleus, which is indicative of induction of cytokine 189 
transcription (8).  RS-ATL8 cells were counted and 105 cells were cultured in 10 mL 190 
MEM (GIBCO, USA), supplemented with 5% vv v/v heat-inactivated FCS (GIBCO, 191 
USA), 100 U/mL penicillin, and 100 µg/mL streptomycin (Sigma, UK) and 2 mM L-192 
glutamine (Sigma, UK) for 48 hours. Cells were grown in 75 cm2 flasks at 37˚C in a 193 
humidified atmosphere with 5% carbon dioxide. 1 mg/mL G418 (Fisher 194 
ThermoScientific, UK) and 600 µg/mL hygromycin B (Invitrogen, Paisley, UK) were used 195 
to maintain expression of human FcεRI genes and NFAT-luciferase, respectively. Prior 196 
to testing, cells were incubated overnight with a 1:50 dilution of human serum from a 197 
healthy atopic donor as a source of IgE. The next day, the sensitized basophils were 198 
stimulated with recombinant M-IPSE, H-IPSEH03 or H-IPSEH06 at concentrations ranging 199 
from 5 to 5000 ng/mL. Luciferase assays were performed 4 hours after activation with 200 
ONE-Glo Luciferase Assay System (Promega, UK), following the manufacturer’s 201 
instructions. The luciferase substrate was added and chemiluminescence was 202 
measured using a microplate reader (Tecan, Spark™ 10M multimode microplate 203 
reader, Tecan, Männedorf, Switzerland) within 30 minutes.  204 
Pain assessment 205 
Visceral pain scores were assigned as previously described (10). The observer 206 
was blinded to mouse treatment assignments prior to assessments. Mice were placed in 207 
clean cages and acclimated for 30 min. For spontaneous pain scoring, mice were 208 
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observed for 60 seconds and given a cumulative spontaneous pain score based on the 209 
following: (0) – normal; (1) – piloerection; (2) – labored breathing; (3) – ptosis; (4) – 210 
licking of abdomen (not grooming); (5) – rounded back.  The maximum possible visceral 211 
pain score is 15. Pain scores were collected at baseline (prior to bladder wall injection), 212 
and 10 hours after ifosfamide was administered. 213 
Von Frey filament testing 214 
Evoked pain scores were collected in a blinded fashion to assess for referred 215 
hyperalgesia. We adopted the up-down approach as previously described (6, 15). An 216 
electronic Von Frey filament (BioSeb, Pinellas Park, Florida) was applied to the right 217 
hind footpad of the mouse for 5 seconds until the mouse displayed rapid withdrawal of 218 
the paw, jumping, or licking of the paw.  The 50% withdrawal threshold was then 219 
calculated from an average of 3 measurements. Results are tabulated as the difference 220 
between baseline and post-ifosfamide values. 221 
Voided Spot on Paper Assay 222 
Voided spot on paper assays were performed as previously described (1, 9, 12, 223 
30). Mice were placed in individual cages 2 hours after ifosfamide or PBS 224 
administration. Whatman paper was cut to the dimensions of the cage floor. The paper 225 
was covered with wire mesh to prevent mice from tearing or ripping the paper. Food 226 
was provided ad libitum in the form of regular chow. Water was not provided to prevent 227 
fluid dripping onto the paper and causing data loss or artifact. Mice were placed under 228 
quiet conditions for 4 hours. They were then returned to normal housing conditions after 229 
completion of the experiment.  The pieces of Whatman paper were converted to .tiff 230 
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images using UV transillumination (Bio-Rad, Hercules, CA). Image analysis was 231 
performed with ImageJ Fiji (https://fiji.sc/). Corner voiding was assessed by assigning 232 
5% of the total paper area to each corner. Central voiding was assessed by assigning 233 
40% of the total area to the center of the filter paper.  234 
In vitro proliferation assays 235 
MB49 cells were counted and plated with equal numbers of cells in each well. H-236 
IPSEH03 or H-IPSEH03NLS were added to the cell media at the following concentrations: 237 
0.0655 pmol (1 ng/ml), 0.655 pmol (10 ng/ml), 6.55 pmol (100 ng/ml), 65.5 pmol (1000 238 
ng/ml), or PBS for control.  5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester 239 
(CFSE) assays were then performed according to manufacturer’s instructions 240 
(Thermofisher Scientific, Waltham, MA). One mL of a single cell suspension for each 241 
experimental condition was then acquired on a BD FACSCanto II machine (BD 242 
Biosciences, San Jose, CA). Flow cytometric analysis was performed using FlowJo 243 
software (Ashland, OR). 244 
Statistical analysis 245 
 246 
One-way ANOVA or Student’s t-test were utilized as appropriate. Post hoc testing was 247 
performed with Bonferroni test. A p-value of less than 0.05 was considered statistically 248 
significant.249 
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Results 250 
Recombinant H-IPSEH03 and H-IPSEH06 proteins activate IgE-bearing basophils in 251 
vitro 252 
 We previously demonstrated that M-IPSE activates basophils in vitro through NF-253 
AT (28). This pathway is implicated in basophil and mast cell expression of IL-4, which 254 
we have observed in vivo in mice administered H-IPSEH06 (19).  Moreover, we have also 255 
noted that ifosfamide-challenged mice given H-IPSEH06 are protected from several 256 
pathogenic aspects of hemorrhagic cystitis in an IL-4-dependent fashion (19). Thus, we 257 
sought to demonstrate that H-IPSEH03 and H-IPSEH06, which are both S. haematobium 258 
orthologs of M-IPSE, also stimulate IL-4-associated reporter gene expression in vitro. 259 
We first purified recombinant H-IPSEH03 and H-IPSEH06 from transfected HEK293-6E 260 
cells. Western blots under non-reducing conditions identified a band with a molecular 261 
weight of 38-40 kDa which corresponds to the homodimeric H-IPSE structure (Figure 262 
2A). Recombinant H-IPSEH03 and H-IPSEH06 protein was then incubated with IgE-263 
loaded basophils. This resulted in NF-AT activation, which is associated with IL-4 264 
secretion in basophils (Figure 2B). Having confirmed that H-IPSEH03 triggers IL-4-265 
associated pathways in cultured basophils, we next sought to determine the therapeutic 266 
efficacy of H-IPSEH03 in the mouse model of ifosfamide-induced hemorrhagic cystitis. 267 
H-IPSEH03 dampens chemotherapy-induced increases in bladder wet weight  268 
We assessed for an increase in bladder wet weight caused by hemorrhage, 269 
edema and cellular infiltration following ifosfamide injection. Ifosfamide administration 270 
caused a statistically significant increase in bladder wet weight compared to controls 271 
(Figure 3A, 3B; n=8, p<0.001) A single H-IPSEH03 bladder wall injection significantly 272 
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reversed the increase in bladder wet weight caused by ifosfamide in bladder wall 273 
injected mice but not mice that received tail vein injection (p=0.02 and N.S., 274 
respectively).  The beneficial effect of IPSEH03 on bladder wet weight was reversed by 275 
anti-IL4 antibody (p<0.001). However, IPSEH03NLS (H-IPSEH03 with a non-functional 276 
nuclear localization sequence) also ameliorated ifosfamide-induced increases in bladder 277 
wet weight, regardless of mode of administration, suggesting that the therapeutic effect 278 
of IPSE on bladder wet weight is mediated by IL-4, but not dependent on IPSE 279 
translocation into the nucleus. Histological analysis was not possible in this model due 280 
to the effects of inflammation induced by bladder wall injection in this surgical model. 281 
Tail vein injection results were distinct from bladder wall injection in two ways. 282 
After tail vein H-IPSEH03 injection bladder wet weights decreased but remained 283 
significantly higher than non-ifosfamide-exposed controls (Figure 2B; p=0.03). 284 
Furthermore, administration of H-IPSENLS to ifosfamide-treated mice demonstrated a 285 
downward trend in bladder wet weight that was not significant compared to mice given 286 
only ifosfamide. 287 
H-IPSEH03 abrogates evoked pain responses in chemotherapy-treated mice 288 
We next sought to determine whether H-IPSEH03 administration had an effect on 289 
ifosfamide-induced bladder pain. We first measured referred hyperalgesia using von 290 
Frey filament testing. Mice injected with ifosfamide had greater evoked pain responses 291 
than those of control mice (Figure 4). H-IPSEH03 bladder wall injection increased the 292 
withdrawal threshold, i.e., reversed allodynia caused by ifosfamide injection (p<0.05). 293 
When neutralizing anti-IL-4 antibody was co-administered with H-IPSEH03, the protective 294 
effect of H-IPSEH03 was attenuated (p<0.05).  Likewise, injection of H-IPSEH03NLS, which 295 
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cannot translocate to the nucleus, also featured a decreased analgesic effect compared 296 
to IPSEH03 (p<0.05). H-IPSEH03 had no effect on referred hyperalgesia when 297 
administered via tail vein injection (data not shown) 298 
H-IPSEH03 does not significantly affect abnormal ifosfamide-induced voiding 299 
patterns in mice 300 
 C57BL/6 mice demonstrate characteristic voiding behavior of voiding 301 
preferentially in cage corners whereas urothelial injury significantly increases central 302 
cage voiding (30). We assessed for voiding dysfunction caused by ifosfamide based on 303 
the percentage of overall voids in the corners of cages. When mice received ifosfamide, 304 
the percentage of corner voids was significantly decreased (Figure 5). H-IPSEH03 305 
increased the frequency of corner voiding in the presence of ifosfamide, but this was not 306 
a statistically significant finding. Administration of α-IL4 antibody reversed the effect of 307 
H-IPSEH03 on corner voiding and was not significantly different from ifosfamide 308 
treatment (p=0.07 vs. control).  309 
Ifosfamide administration non-significantly increased the percentage of voids in 310 
the central area of cages (Figure 5B). H-IPSEH03, α-IL4 antibody or H-IPSEH03NLS did not 311 
have a significant effect on central voiding. H-IPSEH03NLS -treated mice were not 312 
significantly different from ifosfamide-treated or control mice. Tail vein injection of H-313 
IPSEH03 did not significantly improve or alter voiding patterns in ifosfamide-treated mice 314 
(Data not shown).  315 
H-IPSEH03 promotes proliferation of urothelial cells in vitro 316 
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 Given the beneficial effects of H-IPSEH03 on ifosfamide-induced bladder wet 317 
weight increases and pain, as well as prior data indicating a direct effect of H-IPSEH03 318 
on urothelial cells (19), we assessed the effect of H-IPSEH03 on urothelial cell 319 
proliferation by co-incubating H-IPSEH03 with the MB49 (mouse carcinoma-derived 320 
urothelial) cell line. H-IPSEH03 significantly increased cell proliferation over two 321 
successive daughter cell generations compared to controls (Figure 5A; *p<0.05, 322 
**p<0.01, ***p<0.0001; n=8). This held true across a range of H-IPSEH03 concentrations. 323 
In contrast, co-incubation of cells with H-IPSEH03NLS did not cause increased 324 
proliferation over that of controls (Figure 5B).  325 
Downloaded from www.physiology.org/journal/ajprenal at Univ of Nottingham (128.243.002.047) on May 8, 2019.
11 
 
Discussion 326 
 Hemorrhagic cystitis is a common sequela of alkylating chemotherapy, affecting 327 
up to 40% of patients who receive ifosfamide or cyclophosphamide (16). Once 328 
established, hemorrhagic cystitis is a challenging-to-manage entity characterized by 329 
widespread bladder inflammation and leading to hematuria, dysuria, small volume 330 
voids, urinary frequency, and bladder spasms. Currently available medical therapy, 331 
MESNA, has a narrow therapeutic window as it can only be administered immediately 332 
before and during chemotherapy. MESNA can cause hypersensitivity reactions and is 333 
ineffective in treating hemorrhagic cystitis once it has been established (2, 24, 26). 334 
Therefore, novel therapies need to be developed to fulfill this unmet need.  335 
One source of new drugs for hemorrhagic cystitis may be derived from 336 
Schistosoma haematobium. Urogenital schistosomiasis is a parasitic disease in which 337 
Schistosoma haematobium worms lay eggs in the bladder and other pelvic organs. 338 
Deposited eggs must traverse the host bladder wall in order to be released in the urine. 339 
Although urogenital schistosomiasis itself causes a form of hemorrhagic cystitis, 340 
hematuria can be variable or even absent (29). We reasoned that host 341 
immunomodulation by S. haematobium egg products allow the parasite to complete its 342 
life cycle without causing severe morbidity to its host, including hemorrhagic cystitis 343 
(11). Specifically, we postulated that S. haematobium eggs can accomplish this by 344 
secreting H-IPSE orthologs in order to modulate the host immune response.   345 
In a prior study we demonstrated the clinical potential of exploiting the anti-346 
inflammatory and analgesic properties of H-IPSEH06 (19). A single intravenous dose of 347 
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H-IPSEH06 was superior to MESNA in alleviating bladder hemorrhage in ifosfamide-348 
treated mice (19).  349 
Clinical translation of H-IPSEH06, H-IPSEH03, and other IPSE orthologs will require 350 
large-scale recombinant protein production. Herein we show that H-IPSEH03 and H-351 
IPSEH06 can be purified from mammalian HEK293T-6E cells. Furthermore, we 352 
demonstrate that, like M-IPSE, H-IPSEH03 and H-IPSEH06 trigger IgE-bearing basophil 353 
NF-AT activation in vitro, which in turn is linked to IL-4 secretion. H-IPSEH03 injected into 354 
the mouse bladder wall attenuates ifosfamide-induced increases in bladder wet weight 355 
in an IL-4 and NLS-dependent fashion. This suggests that H-IPSEH03 reduces 356 
ifosfamide-induced edema, cellular infiltration, and/or hemorrhage (pathologic 357 
processes which can increase bladder wet weight). When H-IPSEH03 was administered 358 
via tail vein, ifosfamide-induced increases in bladder wet weight were unaffected. 359 
Unsurprisingly, there was neither an IL-4-dependent nor nuclear translocation-360 
dependent effect compared to controls. This is consistent with our prior report that 361 
intravenous administration of H-IPSEH06 did not affect ifosfamide-mediated increases in 362 
bladder wet weight (19). There are several possible explanations for these differences 363 
in effects of bladder wall versus intravenous injections. For instance, bladder wall 364 
injections themselves may cause an increase in hemorrhage, and bladder mass due to 365 
the added weight of the matrigel. This may make it more difficult to discern weight 366 
differences between groups when compared to tail vein injection. Furthermore, bladder 367 
wall injection of H-IPSEH03 may result in high local concentrations but low systemic 368 
levels. We have previously reported that peripheral basophils may play a role in IPSE’s 369 
therapeutic effects in hemorrhagic cystitis (19). Recruitment of circulating basophils to 370 
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the site of inflammation and subsequent IL-4 release may be dependent on the action of 371 
H-IPSE outside of the bladder. Conversely, it is possible that the higher local H-IPSEH03 372 
concentrations achieved by bladder wall injection may more effectively activate bladder 373 
mast cells, basophils, and other cell types critical for therapeutic effects. 374 
Another explanation for the different phenotypes observed between H-IPSEH03 375 
and H-IPSEH06 is that variations in the sequence, and therefore, function of IPSE 376 
proteins have evolved such that different orthologs of H-IPSE are secreted to perform 377 
different host-modulatory functions.  Both orthologs of H-IPSE are homologous to M-378 
IPSE in that they both conserve the C-terminal nuclear localization sequence as well as 379 
7 cysteines which are responsible for forming disulfide bonds to create a homodimeric 380 
structure (22). Characterization of sequence/structure-function relationships of individual 381 
orthologs of H-IPSE is the subject of continued investigation.  382 
Referred hyperalgesia is a unique feature of visceral pain which causes normally 383 
non-painful stimuli to feel painful, even in anatomically distant locations. 384 
Cyclophosphamide/ifosfamide administration in rodents is a well-established model of 385 
referred hyperalgesia (3–5).  We have previously reported that intravenous delivery of 386 
H-IPSEH06 alleviates visceral and referred pain in ifosfamide-treated mice (19). In a 387 
similar fashion, bladder wall-injected H-IPSEH03 alleviated referred hyperalgesia in an 388 
IL-4 and NLS-dependent fashion. Post-operative pain did not affect the differences 389 
observed with H-IPSEH03 administered via bladder wall injection, as we were able to 390 
demonstrate a statistically significant increase in pain threshold (i.e., decreased referred 391 
hyperalgesia) in ifosfamide-treated mice who received H-IPSEH03. This suggests that 392 
bladder wall-injected H-IPSEH03 may have alleviated ifosfamide- and/or surgery-induced 393 
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pain. Tail vein injection of H-IPSEH03 did not result in a significant difference between 394 
treatment groups (data not shown).  395 
The voided spot on paper assay is a well-established, reliable model to assess 396 
lower urinary tract function in mice (1, 9, 12, 30). The characteristic voiding patterns of 397 
C57BL/6 mice consist of large volume voids in the corners of cages, whereas bladder 398 
injury causes mice to void at non-corner edges or the center of cages (30). We 399 
demonstrated that ifosfamide exposure alters voiding behavior by significantly 400 
decreasing corner voiding. This was non-significantly reversed by H-IPSEH03 bladder 401 
wall injection. Ifosfamide-treated mice tended to void in the central part of the cage, 402 
although this was not significant. The voided spot on paper assay results may have 403 
been influenced by surgical intervention and accompanying post-operative pain. Tail 404 
vein injection of H-IPSEH03 did not affect voiding patterns in ifosfamide-treated mice at 405 
all (data not shown). We did not allow mice to drink water during the 4-hour duration of 406 
assay to avoid possible interference of dripping water with collection of urine on filter 407 
paper. Post-operative pain in bladder wall-injected mice, as well as the lack of water 408 
access, may have influenced voiding behavior independent of the effects of IPSE.  409 
We previously demonstrated that H-IPSEH06 induces transcription of uroplakins in 410 
the ifosfamide-injured bladder to a degree similar to or greater than MESNA (19). 411 
Uroplakins are transmembrane proteins implicated in barrier functions, urothelial 412 
proliferation and bladder regeneration (14). Co-incubation of a variety of urothelial cell 413 
lines with H-IPSEH06 significantly increases cell proliferation (data not shown). 414 
Moreover, co-incubation of the urothelial cell line MB49 with H-IPSEH03 induced a much 415 
stronger proliferative response than H-IPSEH06. The pro-proliferative effect of H-IPSEH03 416 
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was nuclear localization sequence-dependent. This supports the notion that H-IPSEH03 417 
may upregulate urothelial repair mechanisms through translocation to the nucleus and 418 
modulation of gene expression. Future work will be directed towards further quantifying 419 
changes in uroplakin and related gene expression induced by H-IPSEH03. 420 
This study has several limitations. For instance, the mechanism by which H-421 
IPSEH03 targets and sequesters chemokines is poorly understood. It is possible that 422 
IPSE’s chemokine-binding properties may play a role in its therapeutic effects in the 423 
ifosfamide-injured bladder independent of IL-4 effects. Furthermore, we have not 424 
elucidated the mechanism by which IPSE exerts its effects outside the bladder. We 425 
chiefly included experiments in which IPSE was delivered directly to the tissue of 426 
interest. It is unclear how the mechanism of action of H-IPSEH03 is different when 427 
administered in a local versus systemic fashion. For example, basophil and mast cell 428 
recruitment to the bladder to release anti-inflammatory IL-4 may be modulated 429 
differently based on the concentration of regional and systemic IPSE. Nuclear 430 
translocation is an important component of the therapeutic effect of IPSE and we have 431 
not yet investigated transcriptional regulation by H-IPSEH03. It is also unclear whether 432 
IPSE operates on a transcriptional level or whether there is a post-translational 433 
component to its mechanism of action. Taken together, chemokine-binding and nuclear 434 
translocation properties of IPSE are not well understood and may mediate some of the 435 
effects reported in this manuscript. Further, we were unable to demonstrate histological 436 
evidence to support our conclusions.  As bladder wall injection was a surgical 437 
intervention performed 24 hours prior to harvesting the tissues, there was significant 438 
intramural artifact present in the sections that was more prominent than urothelial 439 
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changes. Post-surgical inflammation was more robust than the differences we 440 
attempted to observe at this time point, which precluded accurate scoring.  441 
Moreover, these experiments have not provided information as far as duration of 442 
action of IPSEH03 in comparison to MESNA. However, MESNA has a well-known 443 
protective effect against chemotherapy-induced cystitis with an equally well-established 444 
duration of action. We have previously demonstrated that a single systemic dose of 445 
ISPEH06 had a superior protective effect compared to 3 doses of MESNA (19). Duration 446 
of action of H-IPSEH03 via systemic or local injection are areas of ongoing investigation. 447 
In summary, we report the potential therapeutic application of a parasite-derived 448 
protein, H-IPSEH03, to treat hemorrhagic cystitis via bladder wall injection. Detrusor 449 
injection of H-IPSEH03 can be readily applied to humans as other drugs such as 450 
Botulinum Toxin A and bulking agents are delivered directly by bladder wall injection 451 
(21, 25).  Because we have found that IPSE modulates the host immune system to 452 
dampen inflammation as well as pain responses, we speculate that this protein could 453 
potentially be used for broader indications, such as interstitial cystitis and other bladder 454 
pain syndromes.  455 
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Figure Legends 569 
 570 
Figure 1: Bladder wall injection technique. Mice were anesthetized with inhaled 571 
isoflurane. Next their abdomens were depilated and cleaned, injected with local 572 
anesthetic, and a midline laparotomy was performed. The bladder was exteriorized, 573 
stabilized with a cotton applicator, and its wall injected with a 30 gauge needle. 574 
Figure 2: (A) Western blots of purified H-IPSEH03 and H-IPSEH06 proteins demonstrate a 575 
prominent band with a molecular weight of approximately 38-40 kDa. (B) RS-ATL8 576 
basophil NF-AT activation in response to M-IPSE, H-IPSEH03 and H-IPSEH06.  Incubation 577 
of IPSE with IgE-bearing basophils demonstrates that H-IPSE orthologs induce NF-AT 578 
reporter gene expression comparable to M-IPSE. 579 
Figure 3: Effect of H-IPSEH03 on bladder wet weights. Mice received a bladder wall 580 
injection (A) or a tail vein injection (B) with or without H-IPSEH03 or a nuclear localization 581 
sequence mutant of H-IPSEH03 (IPSENLS). Twenty-four hours later, mice were injected 582 
with PBS (control) or ifosfamide (“ifosfamide” or “ifos”). Some mice received neutralizing 583 
anti-IL4 antibody (αIL4) 30 minutes prior to ifosfamide. Bladders were collected and 584 
weighed 12 hours following ifosfamide injection to assess for edema and hemorrhage. 585 
A. Bladder wall injection of H-IPSEH03 significantly decreases ifosfamide-induced 586 
increase in bladder wet weight in an IL-4- but not nuclear translocation-dependent 587 
fashion. *p=0.02, **p<0.006, ***p<0.001. B. Tail vein injection of H-IPSEH03 non-588 
significantly decreases the ifosfamide-induced increase in BWW in an IL-4 but not NLS-589 
dependent fashion. Plotted data are pooled from 3 experiments. Error bars represent 590 
means and one standard deviation. *p=0.01, **p=0.03, ***p<0.001. 591 
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Figure 4: The effect of IPSE bladder wall injections on evoked pain responses (referred 592 
hyperalgesia). H-IPSEH03 bladder wall injection alleviates allodynia (referred 593 
hyperalgesia) associated with hemorrhagic cystitis-associated pain in an IL-4 and NLS-594 
dependent manner. Plotted data are pooled from 3 experiments. Error bars represent 595 
means and one standard deviation. *p=0.04, **p=0.02, ***p=0.01. 596 
Figure 5: Voiding dysfunction caused by ifosfamide was alleviated by bladder wall 597 
injections of H-IPSEH03. Ifosfamide significantly decreased corner voiding (A & C). H-598 
IPSEH03 non-significantly restored the percentage of corner voids in ifosfamide-treated 599 
mice (D). Administration of neutralizing α-IL4 antibody may reverse the non-significant 600 
protective effect of H-IPSEH03 (E). Administration of H-IPSEH03 that cannot localize to the 601 
nucleus has a similar effect on chemotherapy-exposed voiding patterns as wild type H-602 
IPSEH03. Plotted data are pooled from 3 experiments. Error bars represent means and 603 
one standard deviation. **p<0.01. 604 
Figure 6: H-IPSEH03 co-incubation with MB49 cells induced proliferation in an NLS-605 
dependent fashion. (A) When co-incubated with H-IPSEH03, the number of MB49 cells 606 
was markedly increased versus control over 3 generations of cells. Significant increases 607 
in proliferation were observed for both low (0.065 pmol) and high concentrations of H-608 
IPSEH03 (up to 65.5 pmol). (B)  MB49 cellular proliferation was not increased compared 609 
to controls by co-incubation with H-IPSEH03NLS. Error bars represent means and one 610 
standard deviation. *p<0.05, ***p<0.001. 611 
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